Get the Stockscreener App
0.6825
0.63%
0.0265
Novabay Pharmaceuticals Inc stock is traded at $0.6825, with a volume of 7,836.
It is up +0.63% in the last 24 hours and up +14.88% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$0.709
Open:
$0.7097
24h Volume:
7,836
Relative Volume:
0.00
Market Cap:
$3.41M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.0652
EPS:
-10.47
Net Cash Flow:
$-5.04M
1W Performance:
-1.86%
1M Performance:
+14.88%
6M Performance:
-84.49%
1Y Performance:
-93.49%
1-Day Range:
$0.68
$0.7163
1-Week Range:
$0.676
$0.74
52-Week Range:
$0.3611
$11.45
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NBY | 0.705 | 3.41M | 14.64M | -13.74M | -5.04M | -10.47 |
| VRTX | 447.05 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.92 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NovaBay calls for affirmative vote on asset sale and dissolution - Investing.com
NovaBay calls for affirmative vote on asset sale and dissolution By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes - TipRanks
NovaBay Pharmaceuticals Reports Third Quarter 2024 Results, Accepts Revised Offer to Sell Avenova Brand - Vision Monday
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
NovaBay accepts higher PRN offer, says Refresh deal no longer superior - MSN
NovaBay agrees to increased offer for eyecare unit - Investing.com
NovaBay agrees to increased offer for eyecare unit By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price - StockTitan
NovaBay Pharmaceuticals : Signs Distribution Agreement With the Biopharm Group - Marketscreener.com
# NovaBay Pharmaceuticals Considers Acquisition Offer in Recent SEC Filing - Defense World
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions - MSN
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell Its Avenova Assets - Vision Monday
Novabay Pharmaceuticals Inc (NBY) Stock: A Year of Market Fluctuations - The InvestChronicle
Before You Invest, Make Sure You Check This Novabay Pharmaceuticals Inc (AMEX: NBY) Analysis - Stocks Register
Novabay Pharmaceuticals Inc (NBY)’s Market Momentum: Closing Strong at 0.70, Down -5.62 - The Dwinnex
NovaBay Pharmaceuticals, Inc. announced that it expects to receive $2.83 million in funding from Pioneer Pharma Pte. Ltd. and other investors. - Marketscreener.com
A new trading data show Novabay Pharmaceuticals Inc (NBY) is showing positive returns. - SETE News
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - PR Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com - Defense World
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
NBY’s price-to-free cash flow ratio: What it means for investors - US Post News
NovaBay sells Avenova brand to PRN for $9.5 million - Investing.com
PRN Nutriceuticals agreed to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc.. - Marketscreener.com
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders - Business Wire
NovaBay sells Avenova brand to PRN for $9.5 million By Investing.com - Investing.com South Africa
NovaBay Pharma Announces Avenova Sale and Planned Dissolution - TipRanks
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - PR Newswire
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets - StockTitan
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
Impetigo Drugs Global Strategic Business Report 2024 - GlobeNewswire Inc.
Was there any good news for Novabay Pharmaceuticals Inc (NBY) stock in the last session? - US Post News
Novabay Pharmaceuticals Inc Inc. (NBY) Price Performance: The Role of Supply and Demand - The InvestChronicle
NovaBay Pharmaceuticals (NYSE:NBY) Announces Quarterly Earnings Results - Defense World
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2024 Earnings Call Transcript - Insider Monkey
Novabay Pharmaceuticals Inc (NBY)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
NovaBay Pharmaceuticals Reports Mixed Second Quarter 2024 Financial Results - Vision Monday
Earnings call: NovaBay Pharmaceuticals reports growth in eyecare By Investing.com - Investing.com Canada
Earnings call: NovaBay Pharmaceuticals reports growth in eyecare - Investing.com
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Crosses Above 50-Day Moving Average of $0.00 - Defense World
NovaBay To Hold 2017 Second Quarter Conference Call On August 10, 2017 - BioSpace
NBY Stock Earnings: NovaBay Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results - wallstreet:online
Ratio Analysis: Unpacking Novabay Pharmaceuticals Inc (NBY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
NBY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
NovaBay stock hits 52-week low at $0.47 amid steep annual decline - Investing.com
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering - Vision Monday
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024 - StockTitan
Adversity is less terrifying than hope: Novabay Pharmaceuticals Inc (NBY) - SETE News
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):